Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Braveheart Bio, Inc. before investing.

In this article, we go over a few key elements for understanding Braveheart Bio, Inc.’s stock price such as:

• Braveheart Bio, Inc.’s current stock price and volume
• Why Braveheart Bio, Inc.’s stock price changed recently
• Upgrades and downgrades for BRVE from analysts
• BRVE’s stock price momentum as measured by its relative strength

About Braveheart Bio, Inc. (BRVE)

Before we jump into Braveheart Bio, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Want to learn more about Braveheart Bio, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Braveheart Bio, Inc..

Braveheart Bio, Inc.’s Stock Price as of Market Close

As of September 03, 2026, 4:00 PM, CST, Braveheart Bio, Inc.’s stock price was $26.270.

Braveheart Bio, Inc. is down 2.52% from its previous closing price of $26.950.

During the last market session, Braveheart Bio, Inc.’s stock traded between $25.185 and $27.220. Currently, there are approximately 30.06 million shares outstanding for Braveheart Bio, Inc..

Braveheart Bio, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Braveheart Bio, Inc. Stock Price History

Braveheart Bio, Inc.’s (BRVE) price is currently up 3.02% so far this month.

During the month of September, Braveheart Bio, Inc.’s stock price has reached a high of $27.780 and a low of $24.895.

Over the last year, Braveheart Bio, Inc. has hit prices as high as $32.000 and as low as $24.305.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Braveheart Bio, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 02, 2026, there were analysts who downgraded Braveheart Bio, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Braveheart Bio, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Braveheart Bio, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Braveheart Bio, Inc. (BRVE) by visiting AAII Stock Evaluator.

Relative Price Strength of Braveheart Bio, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 02, 2026, Braveheart Bio, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Braveheart Bio, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Braveheart Bio, Inc. Stock Price: Bottom Line

As of September 3, 2026, Braveheart Bio, Inc.’s stock price is $26.270, which is down 2.52% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Braveheart Bio, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.